[Bone marrow transplantation and chimeric antigen receptot T cellular therapy]

Area of Science:

• Oncology
• Immunology
• Cellular Therapy

Background:

• Chemotherapy-resistant malignant hematologic diseases pose a significant clinical challenge.
• Immune cellular therapies present a curative alternative for these refractory cancers.
• Bone marrow transplantation (BMT) and chimeric antigen receptor (CAR)-T cell therapy represent distinct immunologic strategies.

Purpose of the Study:

• To review the landscape of immune cellular therapies for hematologic malignancies.
• To compare the immunologic mechanisms of BMT and CAR-T cell therapy.
• To highlight the ongoing development of CAR-T cell therapies targeting various epitopes.

Main Methods:

• Review of existing literature on immune cellular therapies for hematologic diseases.
• Comparative analysis of BMT and CAR-T cell therapy immunologic principles.
• Summary of current developments in CAR-T cell therapy research.

Main Results:

• BMT induces a broad "pan-immunologic" attack.
• CAR-T cell therapy provides a targeted immunologic attack.
• Immunologic activity in BMT can be modulated by donor cell selection or post-transplant chemotherapy.
• CAR-T cell therapy development is advancing for diverse hematologic clonal diseases.

Conclusions:

• Immune cellular therapy is a viable curative option for resistant hematologic cancers.
• Both BMT and CAR-T cell therapies leverage the immune system to combat hematologic malignancies.
• CAR-T cell therapy development is a promising area for treating clonal hematologic diseases.